Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01432847 · ClinicalTrials.gov registry record
Cell Collection to Study Eye Diseases
A clinical trial of Retinitis Pigmentosa and Retinal Disease, sponsored by National Eye Institute (NEI).
- Recruiting
- Registry status
- 930
- Enrollment target
- 1
- Study location
NCT01432847: Recruiting study of Retinitis Pigmentosa and Retinal Disease, sponsored by National Eye Institute (NEI).
NCT01432847 is a study of Retinitis Pigmentosa and Retinal Disease that is actively recruiting participants, run by National Eye Institute (NEI). The registered enrollment target is 930 participants, above the 236-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (294% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01432847, a study of Retinitis Pigmentosa and Retinal Disease, is actively recruiting participants, sponsored by National Eye Institute (NEI).
- RECRUITING
- Registry status
- 930 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: \- Best Vitelliform Dystrophy (Best disease), Late-Onset Retinal Degeneration (L-ORD), and Age-Related Macular Degeneration (AMD) all affect the retina, the light sensing area at the back of the eye. Doctors cannot safely obtain retinal cells to study these diseases. However, cells collected from hair follicles, skin, saliva, urine, and blood can be used for research. Researchers want to collect cells from people with Best disease, L-ORD, and AMD, and compare their cells with those of healthy volunteers. Objectives: \- To collect hair, skin, saliva, urine, and/or blood samples to study three eye diseases that affect the retina: Best disease, L-ORD, and AMD. Eligibility: * Individuals affected with ocular condition is one year of age or older. * Individuals affected with Best disease, L-ORD, or AMD is 18 years of age or older. * Unaffected individuals are seven years of age or older. Design: * The study requires one visit to the National Eye Institute. * Participants will be screened with a medical and eye disease history. They may also have an eye exam. * Participants will provide a hair sample, saliva sample, urine sample, blood sample, and/or a skin biopsy. The hair will be collected from the back of the head, and the skin will be collected from the inside of the upper arm.
Primary Outcome
The participant-specific ocular cells will be used to perform high throughput drug screens to identify novel potential therapeutic compounds.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 930 participants |
| Start Date | 2011-09-07 |
What NCT01432847 shows while recruiting
NCT01432847 is an observational study that tracks outcomes without assigning an intervention. The registered 930 participants enrollment target is mid-sized for trials with a published cap, above the 236-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (294% higher).
The record links to 4 conditions, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 0 interventions.
NCT01432847 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT01432847 about?
NCT01432847 is a clinical study titled "Cell Collection to Study Eye Diseases". Background: \- Best Vitelliform Dystrophy (Best disease), Late-Onset Retinal Degeneration (L-ORD), and Age-Related Macular Degeneration (AMD) all affect the retina, the light sensing area at the back of the eye. Doctors cannot safely obtain retinal cells to study these diseases. However, cells coll...
What is the current status of trial NCT01432847?
This trial is currently recruiting. The enrollment target is 930 participants. The study started on 2011-09-07.
What conditions does trial NCT01432847 study?
This clinical trial studies the following conditions: Retinitis Pigmentosa, Retinal Disease, Retinal Degeneration, AMD.
Who is sponsoring clinical trial NCT01432847?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01432847 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinitis Pigmentosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01432847's enrollment target sits among peer trials
930 3rd of 37 higher than 35 of 37 other Retinitis Pigmentosa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Retinitis Pigmentosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Promising ROd-cone DYstrophy Gene therapY
RECRUITING · Phase 1
-
High Resolution Retinal Imaging
RECRUITING
-
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
RECRUITING · Phase 2
-
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
RECRUITING
-
Retinal Imaging in Patients With Inherited Retinal Degenerations
RECRUITING
-
Adaptive Optics Imaging of Outer Retinal Diseases
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05216432 · 930 participants · Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- NCT06932029 · 930 participants · NA
SMBP Study: Improving High Blood Pressure in Older Adults With Multiple Chronic Diseases
- NCT07235085 · 930 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
- NCT06555029 · 929 participants · NA
Oral Health Intervention in Adult Primary Care
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI